{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:43:10Z","timestamp":1787787790955,"version":"build-2784847793"},"reference-count":56,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Phosphaturic mesenchymal tumors (PMT) are rare neoplasms, which can give rise to a multifaceted syndrome, otherwise called tumor-induced osteomalacia (TIO). Localizing these tumors is crucial to obtain a cure for the phosphate metabolism derangement, which is often the main cause leading the patient to seek medical help, because of invalidating physical and neuromuscular symptoms. A proportion of these tumors is completely silent and may grow unnoticed, unless they become large enough to produce pain or discomfort. FGF-23 can be produced by several benign or malignant PMTs. The phosphate metabolism, radiology and histology of these rare tumors must be collectively assessed by a multidisciplinary team aimed at curing the disease locally and improving patients\u2019 quality of life. This narrative review, authored by multiple specialists of a tertiary care hospital center, will describe endocrine, radiological and histological features of these tumors, as well as present surgical and interventional strategies to manage PMTs.<\/jats:p>","DOI":"10.3390\/curroncol30080541","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T12:45:53Z","timestamp":1691498753000},"page":"7478-7488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phosphaturic Mesenchymal Tumors with or without Phosphate Metabolism Derangements"],"prefix":"10.3390","volume":"30","author":[{"given":"Andrea","family":"Montanari","sequence":"first","affiliation":[{"name":"Orthopaedics and Traumatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Pirini","sequence":"additional","affiliation":[{"name":"Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Lotrecchiano","sequence":"additional","affiliation":[{"name":"Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Di Prinzio","sequence":"additional","affiliation":[{"name":"Orthopaedics and Traumatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-2070","authenticated-orcid":false,"given":"Guido","family":"Zavatta","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.semdp.2019.07.002","article-title":"Phosphaturic mesenchymal tumors: A review and update","volume":"36","author":"Folpe","year":"2019","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJM197007092830204","article-title":"Hypophosphatemic Osteomalacia Associated with Nonendocrine Tumors","volume":"283","author":"Salassa","year":"1970","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0002-9343(84)90112-8","article-title":"Oncogenous osteomalacia: Review of the world literature of 42 cases and report of two new cases","volume":"77","author":"Ryan","year":"1984","journal-title":"Am. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4158\/EP10151.OR","article-title":"Tumor-induced osteomalacia: A single center experience","volume":"17","author":"Jagtap","year":"2011","journal-title":"Endocr. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s100240050008","article-title":"Phosphaturic Mesenchymal Tumor-Induced Rickets","volume":"3","author":"Arnsmeier","year":"2000","journal-title":"Pediatr. Dev. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMcpc010029","article-title":"Case 29-2001","volume":"345","author":"Terek","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","article-title":"Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases","volume":"111","author":"Bosman","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"ref_10","first-page":"33","article-title":"Osteomalacia with Looser\u2019s nodes (Milkman\u2019s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years","volume":"16","author":"McCance","year":"1947","journal-title":"Q. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2007020143","article-title":"Hypophosphatemia","volume":"18","author":"Brunelli","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archinte.1988.00380010155016","article-title":"Severe Hypophosphatemia in Hospitalized Patients","volume":"148","author":"Halevy","year":"1988","journal-title":"Arch. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the Hypophosphatemic Patient","volume":"97","author":"Imel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zavatta, G., Altieri, P., Vandi, G., Vicennati, V., Pagotto, U., and Vescini, F. (2021). Phosphate Metabolism and Pathophysiology in Parathyroid Disorders and Endocrine Tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312975"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1359\/jbmr.1997.12.2.159","article-title":"Cellular and Molecular Mechanisms of Renal Phosphate Transport","volume":"12","author":"Tenenhouse","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00223-009-9275-1","article-title":"Bone Turnover and the Osteoprotegerin\u2013RANKL Pathway in Tumor-Induced Osteomalacia: A Longitudinal Study of Five Cases","volume":"85","author":"Rendina","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/jbmr.4325","article-title":"Impaired bone microarchitecture and strength in patients with tumor-induced osteomalacia","volume":"36","author":"Zanchetta","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone Turnover Markers: Basic Biology to Clinical Applications","volume":"44","author":"Schini","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.bonr.2021.101142","article-title":"High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: A case series","volume":"15","author":"Kilbane","year":"2021","journal-title":"Bone Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1020858","DOI":"10.3389\/fphar.2022.1020858","article-title":"Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism","volume":"13","author":"Xiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s40618-018-0849-5","article-title":"Phosphaturic mesenchymal tumors: What an endocrinologist should know","volume":"41","author":"Boland","year":"2018","journal-title":"J. Endocrinol. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","article-title":"Tumor-induced osteomalacia","volume":"294","year":"2005","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ckj\/sfu004","article-title":"Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level","volume":"7","author":"Amblee","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5414\/CN108596","article-title":"Tumor induced osteomalacia: Associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23","volume":"85","author":"Bansal","year":"2016","journal-title":"Clin. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/er.2005-0019","article-title":"The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23","volume":"27","author":"White","year":"2006","journal-title":"Endocr. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI18563","article-title":"Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent","volume":"112","author":"Berndt","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.4465","article-title":"Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour","volume":"235","author":"Lee","year":"2015","journal-title":"J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","article-title":"Characterization of FN1\u2013FGFR1 and novel FN1\u2013FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors","volume":"29","author":"Lee","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_30","first-page":"309","article-title":"Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia","volume":"293","author":"Minisola","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_31","first-page":"4970","article-title":"CT and MR imaging features in phosphaturic mesenchymal tumor-mixed connective tissue: A case report","volume":"15","author":"Shi","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_32","first-page":"E11","article-title":"Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: Case report and review of the literature","volume":"89","author":"Peterson","year":"2010","journal-title":"Ear Nose Throat J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1148\/radiol.10090702","article-title":"Case 165: Oncogenic Osteomalacia","volume":"258","author":"Hendry","year":"2011","journal-title":"Radiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.anndiagpath.2012.06.005","article-title":"Phosphaturic mesenchymal tumor: A report of 6 patients treated at a single institution and comparison with reported series","volume":"17","author":"Fatani","year":"2013","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in Localization of Tumor Causing Oncogenic Osteomalacia","volume":"40","author":"Agrawal","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia","volume":"101","author":"Sadowski","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2463\/mrms.2011-0006","article-title":"Whole-body MR Imaging in Detecting Phosphaturic Mesenchymal Tumor (PMT) in Tumor-induced Hypophosphatemic Osteomalacia","volume":"12","author":"Nakanishi","year":"2013","journal-title":"Magn. Reson. Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00256-018-3014-5","article-title":"Imaging features of phosphaturic mesenchymal tumors","volume":"48","author":"Broski","year":"2018","journal-title":"Skelet. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/rheumatology\/39.12.1415","article-title":"Four cases of acquired hypophosphataemic (\u2018oncogenic\u2019) osteomalacia. Problems of diagnosis, treatment and long-term management","volume":"39","author":"Clunie","year":"2000","journal-title":"Rheumatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002560000306","article-title":"Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia","volume":"30","author":"Ogose","year":"2001","journal-title":"Skelet. Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.anl.2008.01.003","article-title":"Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue","volume":"36","author":"Uramoto","year":"2009","journal-title":"Auris Nasus Larynx"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1210\/jc.2006-2865","article-title":"Determination of the Elimination Half-Life of Fibroblast Growth Factor-23","volume":"92","author":"Khosravi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr. -Relat. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc070347","article-title":"Radiofrequency Ablation of a Tumor Causing Oncogenic Osteomalacia","volume":"357","author":"Hesse","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_45","first-page":"20","article-title":"Radiofrequency Ablation for the Treatment of Phosphaturic Mesenchymal Tumours: A Case Series","volume":"9","author":"Sutcliffe","year":"2017","journal-title":"J. Bone Oncol."},{"key":"ref_46","first-page":"307","article-title":"Percutaneous Radiofrequency Ablation for Phosphaturic Mesenchymal Tumors: A Case Report and Literature Review","volume":"32","author":"Li","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity: An analysis of 32 cases and a comprehensive review of the literature","volume":"28","author":"Folpe","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2265.1992.tb02342.x","article-title":"Oncogenous osteomalacia and malignancy","volume":"37","author":"Harvey","year":"1992","journal-title":"Clin. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","article-title":"Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets","volume":"59","author":"Weidner","year":"1987","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/PAS.0000000000000890","article-title":"Phosphaturic Mesenchymal Tumors: Clinicopathologic, Immunohistochemical and Molecular Analysis of 22 Cases Expanding their Morphologic and Immunophenotypic Spectrum","volume":"41","author":"Agaimy","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_51","first-page":"5172131","article-title":"TIO Associated with Hyperparathyroidism: A Rarity, a Rule, or a Novel HPT-PMT Syndrome\u2014A Case Study with Literature Review","volume":"2021","author":"Salim","year":"2021","journal-title":"Case Rep. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the Treatment of Tumor-Induced Osteomalacia","volume":"36","author":"Miller","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients with Tumor-Induced Osteomalacia","volume":"36","author":"Imanishi","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00223-022-00987-9","article-title":"The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations","volume":"112","author":"Heijboer","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/gcc.23092","article-title":"Successful treatment with MEK-inhibitor in a patient with NRAS -related cutaneous skeletal hypophosphatemia syndrome","volume":"61","author":"Carli","year":"2022","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1021\/acs.jcim.2c00633","article-title":"Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to \u03b1-Klotho","volume":"62","author":"Liu","year":"2022","journal-title":"J. Chem. Inf. Model."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/8\/541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:27:46Z","timestamp":1760128066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/8\/541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["curroncol30080541"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30080541","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}